Adaptive Biotechnologies
ADPT
190 hedge funds and large institutions have $769M invested in Adaptive Biotechnologies in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 59 increasing their positions, 75 reducing their positions, and 34 closing their positions.
82% more call options, than puts
Call options by funds: $726K | Put options by funds: $398K
2.56% more ownership
Funds ownership: 95.08% → 97.64% (+2.6%)
10% less funds holding
Funds holding: 210 → 190 (-20)
16% less capital invested
Capital invested by funds: $921M → $769M (-$151M)
21% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 75
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
53% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$37.8M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$6.98M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.41M |
| 4 |
DP
DDD Partners
Bellevue,
Washington
|
+$5.18M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$4.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.19M |
| 2 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$4.32M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.77M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.57M |
| 5 |
SIG
Senator Investment Group
New York
|
-$3.35M |
ADPT Hedge Fund Activity: Q3 2023 in Review
190 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q3 2023, worth a combined $769M — down 16% from $921M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ADPT and 16 opened new positions — a net loss of 18 holders — while 75 trimmed existing stakes and 59 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $37.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $8.19M.
- 190 institutional investors held Adaptive Biotechnologies (ADPT) as of Q3 2023, down from 210 in Q2 2023.
- Funds reported $769M of Adaptive Biotechnologies stock for Q3 2023, down 16% quarter-over-quarter.
- 16 funds opened new Adaptive Biotechnologies positions in Q3 2023 and 34 closed out, a net change of -18 holders.
- The largest Adaptive Biotechnologies buyer in Q3 2023 was Point72 Asset Management, an estimated $37.8M added.
- The largest Adaptive Biotechnologies seller in Q3 2023 was T. Rowe Price Associates, an estimated $8.19M sold.
Based on aggregated 13F filings for Q3 2023.